Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: Results of a double-blind, placebo-controlled randomized trial
Authors:
- Henry M. RinderHRHenry M. Rinder
- Stuart D. KatzSKStuart D. Katz
- 1 September 2007
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 154 (3) , 494.e1-494.e7
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Expression of the erythropoietin receptor in human heartThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Cardioprotection by Recombinant Human Erythropoietin Following Acute Experimental Myocardial Infarction: Dose Response and Therapeutic WindowCardiovascular Drugs and Therapy, 2005
- Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injuryThe FASEB Journal, 2004
- Molecular Biology of ErythropoietinInternal Medicine, 2004
- A novel protective effect of erythropoietin in the infarcted heartJournal of Clinical Investigation, 2003
- Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingProceedings of the National Academy of Sciences, 2003
- The Cellular Biology of Erythropoietin ReceptorsThe Oncologist, 2003
- Erythropoietin: Physiology and Pharmacology UpdateExperimental Biology and Medicine, 2003
- Neuroprotective properties of epoetin alfaNephrology Dialysis Transplantation, 2002
- Why is erythropoietin made in the kidney? The kidney functions as a critmeterAmerican Journal of Kidney Diseases, 2001